Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170866 | 0.76 | — | — | |
| 2-Pyrrolidone SCHEMBL4655461 | 0.70 | OR51E2 (0.88) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL3356160 | 0.70 | — | — | |
| 2-Pyrrolidone SCHEMBL2389 | 0.70 | — | — | |
| 2-Pyrrolidone SCHEMBL9304498 | 0.70 | OR51E2 (1.00) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL27827832 | 0.70 | — | — | |
| 2-Pyrrolidone SCHEMBL2167448 | 0.70 | OR51E2 (1.00) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL4299593 | 0.70 | — | — | |
| Hydroquinone SCHEMBL11841825 | 0.69 | OR51E2 (0.68) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL8026133 | 0.68 | OR51E2 (0.48) | OR51E2CRBNFKBP5KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492416-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB Biopharma SRL (BE) | 2012-02-09 | — | — | US | disclosed |
| US-8034958-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UOB Pharma, S.A. (BE) | 2011-10-11 | — | — | US | disclosed |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2010-09-02 | — | — | US | disclosed |
| US-7692028-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-04-06 | — | — | US | disclosed |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2008-04-24 | — | — | US | disclosed |
| US-7358276-B2 | for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent | UCB, S.A. (BE) | 2008-04-15 | — | — | US | disclosed |
| EP-1265862-B1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB SA (BE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577296-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use | UCB S.A. (BE) | 2005-09-21 | — | — | EP | disclosed |
| US-20050171188-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2005-08-04 | — | — | US | disclosed |
| US-6911461-B2 | For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse | UCB, S.A. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-6806287-B2 | NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE | UCB, S.A. (BE) | 2004-10-19 | — | — | US | disclosed |
| EP-1452524-A1 | \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ | UCB, S.A. (BE) | 2004-09-01 | — | — | EP | disclosed |
| US-6784197-B2 | SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS | UCB S.A. (BE) | 2004-08-31 | — | — | US | disclosed |
| EP-1447399-A1 | \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ | UCB, S.A. (BE) | 2004-08-18 | — | — | EP | disclosed |
| US-20040116507-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB Biopharma SRL (BE) | 2004-06-17 | — | — | US | disclosed |
| US-20040087646-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2004-05-06 | — | — | US | disclosed |
| US-20030120080-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB Biopharma SRL (BE) | 2003-06-26 | — | — | US | disclosed |
| EP-1265862-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001062726-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | OR51E2 3337/4885CRBN 3099/4885FKBP5 21/4885 |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | OR51E2 3337/4885CRBN 3099/4885FKBP5 21/4885 |
| US-20050171188-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | OR51E2 3337/4885CRBN 3099/4885FKBP5 21/4885 |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | CYP1B1, OGDH, CYP1A2 | OR51E2 3337/4885CRBN 3099/4885FKBP5 21/4885 |
| US-20030120080-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, CYP1A2, OGDH | OR51E2 3390/4885CRBN 2908/4885FKBP5 29/4885 |
| US-20040087646-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, CYP1A2, OGDH | OR51E2 3394/4885CRBN 3040/4885FKBP5 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.